Ivey Business School (Canada)
-
Change at Pfizer: Jeff Kindler (C) Post Wyeth Acquisition Organization
Michael J. Rouse; Chander SehgalCase IVEY-9B10M054-EStrategyThis case is a supplement to Change at Pfizer: Jeff Kindler (A).Starting at €5.74
-
GSK’s Andrew Witty: Addressing Neglected Tropical Diseases and Global Health Issues — Open Labs, Open Minds (B)
Michael J. Rouse; Chander SehgalCase IVEY-9B10M110-EStrategyThis case is a supplement to GSK’s Andrew Witty (A).Starting at €5.74
-
UCB: Data is the New Drug
Stijn ViaeneCase IVEY-9B18E002-EInformation TechnologiesAt the end of 2012, the chief information officer (CIO) at UCB, a global pharmaceutical company based in Brussels, started to implement analytics as a service. Between 2012 and 2016, he put this vision into practice, introducing agile sprints and proving the competence of analytics within the organization, and at the beginning of 2016, he felt the company was ready to upgrade its analytics capability. As he prepared to meet with UCB’s chief execu...Starting at €8.20
-
GSK’s Andrew Witty: Addressing Neglected Tropical Diseases and Global Health Issues — The Pharmaceutical Patent Pool (A)
Michael J. Rouse; Chander SehgalCase IVEY-9B10M109-EStrategyIn February 2009, Andrew Witty, CEO of GlaxoSmithKline (GSK), reflected on his vision for big pharma as a catalyst for change which focussed on two key issues: 1) promoting innovation for the products that treat or prevent neglected tropical diseases and 2) improving access to medicines in the world’s poorest countries. He had announced the creation of the Pharmaceutical Patent Pool and wondered if it was the right strategy to deliver results on ...Starting at €8.20
-
KPN: How to Navigate the Digital Tides
Stijn ViaeneCase IVEY-9B19M046-EStrategyIn June 2018, the executive vice-president of Networks and Information Technology of KPN BV (KPN), Bouke Hoving, was evaluating the digital transformation of KPN, the leading telecommunications company in the Netherlands. Hoving had been an initiator of a turnaround that had started at KPN in 2014, after a financially and operationally hectic year. The entry into the market of over-the-top digital services, which used the Internet to bypass platf...Starting at €8.20
-
Change at Pfizer: Jeff Kindler (A)
Michael J. Rouse; Chander SehgalCase IVEY-9B10M014-EStrategyPfizer Inc., the largest research-based drug company in the world, was faced with multiple challenges, including fierce court battles with generic drug companies over the patents of Lipitor, reduced productivity from research and development, and a changing external health care environment globally, with growing importance of emerging markets. These challenges were set within a business environment characterized by multi-level change and uncertai...Starting at €8.20
-
Change at Pfizer: Jeff Kindler (B) The Wyeth Acquisition
Michael J. Rouse; Chander SehgalCase IVEY-9B10M053-EStrategyThis supplement to Change at Pfizer: Jeff Kindler (A) deals with Pfizer’s 2009 acquisition of Wyeth — the first mega-acquisition since the world economic crisis.Starting at €5.74